CEACAM1 and melanoma: This immunophenotyping panel was used to characterize the cell types that expressed CEACAM1 on peripheral blood mononuclear cells (PBMC) of 5 healthy donors (HD), PBMC from 7 treatment-naive (PBMC-N), and 3 treatment-resistant (PBMC-R) melanoma patients and cells contained within metastatic lesions to lymph node or soft tissues from 9 treatment-naive (Tumor-N) and 10 treatment-resistant (Tumor-R) samples (Supplementary Table 1).